RX-3117 regulatory update

FDA granted Orphan Drug designation to Rexahn's RX-3117 to treat pancreatic cancer. RX-3117 is in a Phase Ib trial for advanced or metastatic solid tumors, which Rexahn expects to complete next quarte...